NDAINTRAVENOUSSOLUTIONPriority Review
Approved
Dec 2015
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Clinical Trials
20
Data completeness
6/8 — Strong
Priority Review
BRIDION (sugammadex) by Merck & Co. is cyclodextrin. Approved for neuromuscular blockade reversal, general anesthesia, postoperative residual curarization and 1 more indications. First approved in 2015.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BRIDION (sugammadex) is an intravenous cyclodextrin that reverses neuromuscular blockade induced by rocuronium and vecuronium by forming a complex with these agents, reducing their availability at the neuromuscular junction. It is used in general anesthesia to rapidly reverse postoperative residual curarization and restore neuromuscular function after surgery. The drug enables faster patient recovery and reduces anesthesia-related complications in the operating room.
LOE Approaching1.6 years to LOE
Product approaching loss of exclusivity (LOE) in ~1.6 years; expect team contraction and shift from growth to defensive strategies.
Mechanism of Action
cyclodextrin. It forms a complex with the neuromuscular blocking agents rocuronium and vecuronium, and it reduces the amount of neuromuscular blocking agent available to bind to nicotinic cholinergic receptors in the neuromuscular junction. This results in the reversal of neuromuscular blockade…
Indications (4)
Worked on BRIDION at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.